trending Market Intelligence /marketintelligence/en/news-insights/trending/4CuYzT8cCz6urVH3t4DIYQ2 content esgSubNav
In This List

Verona Pharma appoints chief medical officer

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Verona Pharma appoints chief medical officer

Verona Pharma PLC named Kathleen Rickard its chief medical officer, effective Feb. 1.

In her new role, Rickard will oversee development of Verona Pharma's drug RPL554, a maintenance treatment of chronic obstructive pulmonary disease, cystic fibrosis and possibly asthma.

Rickard has 25 years of experience in clinical research in respiratory medicine, Verona said in a news release. She was previously head of clinical development at Circassia Pharmaceuticals plc. She was also the chief medical officer at Sweden-based medical technology company Aerocrine AB.

London-based Verona Pharma develops and commercializes therapies for respiratory diseases with significant unmet medical needs.